{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:51:27Z","timestamp":1791219087919,"version":"4.1.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:00:00Z","timestamp":1519344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:named-content content-type=\"genus-species\">Candida auris<\/jats:named-content>\n            is an emerging multidrug-resistant yeast that has been responsible for invasive infections associated with high morbidity and mortality.\n            <jats:named-content content-type=\"genus-species\">C. auris<\/jats:named-content>\n            strains often demonstrate high fluconazole and amphotericin B MIC values, and some strains are resistant to all three major antifungal classes. We evaluated the susceptibility of 16\n            <jats:named-content content-type=\"genus-species\">C. auris<\/jats:named-content>\n            clinical strains, isolated from a wide geographical area, to 10 antifungal agents, including APX001A, a novel agent that inhibits the fungal protein Gwt1 (glycosylphosphatidylinositol-anchored wall transfer protein 1). APX001A demonstrated significantly lower MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            values (0.004 and 0.031 \u03bcg\/ml, respectively) than all other agents tested. The efficacy of the prodrug APX001 was evaluated in an immunocompromised murine model of disseminated\n            <jats:named-content content-type=\"genus-species\">C. auris<\/jats:named-content>\n            infection. Significant efficacy (80 to 100% survival) was observed in all three APX001 treatment groups versus 50% survival for the anidulafungin treatment group. In addition, APX001 showed a significant log reduction in CFU counts in kidney, lung, and brain tissue (1.03 to 1.83) versus the vehicle control. Anidulafungin also showed a significant log reduction in CFU in the kidneys and lungs (1.5 and 1.62, respectively) but did not impact brain CFU. These data support further clinical evaluation of this new antifungal agent.\n          <\/jats:p>","DOI":"10.1128\/aac.02319-17","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T12:06:34Z","timestamp":1515413194000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":135,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Evaluation of the Antifungal Activity of APX001A\/APX001 against Candida auris"],"prefix":"10.1128","volume":"62","author":[{"given":"Christopher L.","family":"Hager","sequence":"first","affiliation":[{"name":"Center for Medical Mycology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L.","family":"Larkin","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Long","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Zohra Abidi","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Center for Medical Mycology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6544e1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw691"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2017.127"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00921-17"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2008.00083.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.131765"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2106.150270"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-016-0132-5"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S116229"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-11"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R700002-JLR200"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/cb300235m"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05414-11"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00291-11"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00570-11"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.05.001"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr342"},{"key":"e_1_3_2_19_2","article-title":"In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210","author":"Hata K","year":"2011","unstructured":"Hata K, Horii T, Miyazaki M, Watanabe NA. 2011. In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210. Intersci Conf Antimicrob Agents Chemother, abstr F1-1377.","journal-title":"Intersci Conf Antimicrob Agents Chemother, abstr F1-1377"},{"key":"e_1_3_2_20_2","article-title":"In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals","author":"Watanabe NA","year":"2011","unstructured":"Watanabe NA, Horii T, Miyazaki M, Hata K. 2011. In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals. Intersci Conf Antimicrob Agents Chemother, abstr F1-1378.","journal-title":"Intersci Conf Antimicrob Agents Chemother, abstr F1-1378"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Gebremariam T Alkhazraji S Alqarihi A Wiederhold NP Shaw KJ Patterson TF Filler SG Ibrahim A. 2017. APX001 protects immunosuppressed mice from Rhizopus delemar infection. Abstr IDweek 2017 poster 1521.","DOI":"10.1093\/ofid\/ofx163.1217"},{"key":"e_1_3_2_22_2","article-title":"Efficacy of oral APX001 in a murine model of cryptococcal meningitis","author":"Schell WA","year":"2017","unstructured":"Schell WA, Giamberardino C, Shaw KJ, Perfect JR. 2017. Efficacy of oral APX001 in a murine model of cryptococcal meningitis. Abstr IDweek 2017, poster 1529,","journal-title":"Abstr IDweek 2017"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2015.05.006"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02396-16"},{"key":"e_1_3_2_25_2","unstructured":"Larkin EL Long L Ghannoum MA. 2017. Susceptibility of recent Candida auris isolates to the novel echinocandin CD101 and comparator antifungal agents. Abstr ECCMID 2017 poster 9037."},{"key":"e_1_3_2_26_2","volume-title":"supplement M59","author":"CLSI","year":"2016","unstructured":"CLSI. 2016. Epidemiological cutoff values for antifungal susceptibility testing, 1st ed, supplement M59. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"1"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Hodges MR Ople E Shaw KJ Mansbach RS van Marle S van Hoogdalem E Kramer W Wedel P. 2017. Phase 1 study to assess safety tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability. Abstr IDweek 2017 poster 1860.","DOI":"10.1093\/ofid\/ofx163.1390"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Hodges MR Ople E Shaw KJ Mansbach RS van Marle S van Hoogdalem E Wedel P Kramer W. 2017. First-in-human study to assess safety tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects. Abstr IDweek 2017 poster 1840.","DOI":"10.1093\/ofid\/ofx163.1370"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03944-14"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01061-07"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/11585270-000000000-00000"},{"key":"e_1_3_2_32_2","unstructured":"Berkow EL Le N Peterson J Garvey EP Yates CM Schotzinger RJ Lockhart SR. 2017. In vitro activity of a novel Cyp51 inhibitor VT-1598 against clinical isolates of Candida auris . Abstr ASM Microbe poster 304."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00435-17"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Mansbach RS Shaw KJ Hodges MR Coleman S Fitzsimmons ME. 2017. Absorption distribution and excretion of [14C]-APX001 after single-dose administration to rats and monkeys. Abstr IDweek 2017 poster 1513.","DOI":"10.1093\/ofid\/ofx163.1209"},{"key":"e_1_3_2_35_2","volume-title":"Document M27-A3","author":"CLSI","year":"2008","unstructured":"CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. Document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02319-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02319-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:04:35Z","timestamp":1645477475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02319-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1128\/AAC.02319-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02319-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"2017-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02319-17"}}